Compare Sana Biotechnology Inc (SANA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Charles Schwab Corporation Common Stock — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Charles Schwab Corporation Common Stock trades at $106.54 (market cap $184.81B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 179.4× Sana Biotechnology Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.2% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SCHW | |
|---|---|---|
Market Cap | $1.03B | $184.81B |
Sector | Health | Financials |
52-Week High | $5.92 | $113.65 |
52-Week Low | $2.68 | $85.35 |
Enterprise Value | $946.04M | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Charles Schwab (SCHW) trades at $106.87, down 2.21% with a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $1.62 vs. $1.56 expected, continuing a trend of earnings beats. Revenue grew to $23.92B in 2025 with a robust 38.79% net income margin. Analyst consensus is bullish with 57% buy ratings and a $122.14 price target, representing 14% upside potential.
SCHW presents a compelling investment case with strong earnings momentum and expanding digital asset offerings, though near-term technical weakness and competitive pressures in the RIA custody space warrant caution. The company's diversified revenue streams and improving cash flow trends support long-term growth prospects despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
